Cellular Senescence in Neurodegeneration

Overview

Cellular senescence is a state of irreversible cell-cycle arrest triggered by various forms of cellular stress, including DNA damage, telomere shortening, oncogenic activation, and oxidative stress. Originally characterized as a tumor-suppressive mechanism, cellular senescence has emerged over the past decade as a major driver of organismal aging and a contributing factor to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia.

Senescent cells accumulate in the aging brain and in disease-affected regions where they exert deleterious effects through two principal mechanisms: the loss of cellular function (cells that would normally support tissue homeostasis enter a permanently arrested state) and the acquisition of a pro-inflammatory secretory phenotype. This secretory program, known as the senescence-associated secretory phenotype (SASP), produces a complex cocktail of cytokines, chemokines, growth factors, matrix metalloproteinases, and extracellular vesicles that drive chronic neuroinflammation, disrupt synaptic function, impair neurogenesis, and spread senescence to neighboring cells through paracrine signaling [@wiley2019].

The therapeutic targeting of senescent cells using senolytic drugs (agents that selectively induce apoptosis in senescent cells) or senomorphic agents (compounds that suppress the SASP without killing senescent cells) represents one of the most actively investigated frontiers in neurodegenerative disease research. Early-phase clinical trials are now evaluating senolytics in human subjects with Alzheimer’s disease and related conditions [@ochab2024].

Molecular Mechanisms of Senescence Induction

DNA Damage Response

The DNA damage response (DDR) is the central trigger of cellular senescence in post-mitotic tissues such as the brain. Persistent DNA lesions—whether arising from oxidative damage, replication stress, or environmental genotoxins—activate the ATM/ATR kinase cascade, which stabilizes the tumor suppressor protein p53. Activated p53 transcriptionally upregulates p21 (CDKN1A), which inhibits cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 4/6 (CDK4/6), leading to hypophosphorylation of the retinoblastoma protein (Rb) and permanent G1 cell-cycle arrest [@bhat2012].

Unlike transient cell-cycle arrest, which allows cells to repair DNA damage and resume proliferation, senescence-associated arrest is irreversible. The permanence of senescence depends on the epigenetic silencing of cell-cycle genes through the formation of senescence-associated heterochromatin foci (SAHF), which compact chromatin and suppress proliferation-promoting transcripts [@hernandezsegura2018].

In neurons, which are terminally differentiated and do not normally replicate, DNA damage and DDR activation trigger a senescence-like state characterized by SASP factor secretion, mitochondrial dysfunction, and increased expression of cell-cycle regulators despite the absence of cell division. This phenomenon, sometimes termed “senescence without proliferation,” has been documented in Alzheimer’s disease and Parkinson’s disease brain tissue and is associated with cognitive decline and motor dysfunction [@baker2018].

The p16INK4a/Rb and p53/p21 Pathways

Two interconnected tumor suppressor pathways mediate the canonical senescence arrest:

p53/p21 pathway (DNA damage sensor): DNA damage → ATM/ATR activation → CHK1/CHK2 → p53 phosphorylation → p21 (CDKN1A) transcription → CDK2 inhibition → Rb hypophosphorylation → G1 arrest [@bhat2012].

p16INK4a/Rb pathway (stress sensor): Chronic stress → p16INK4a (CDKN2A) upregulation → CDK4/6 inhibition → Rb hypophosphorylation → G1 arrest [@sharpless2015].

The p16INK4a protein is widely used as the most reliable molecular marker of cellular senescence in aging and disease tissues. In the aging brain, p16INK4a-positive cells increase dramatically, accounting for a significant fraction of microglia, astrocytes, and endothelial cells. In Alzheimer’s disease and Parkinson’s disease brains, p16INK4a expression is elevated in specific regions vulnerable to neurodegeneration, including the hippocampus, substantia nigra pars compacta, and prefrontal cortex [@mathur2016].

Mitochondrial Dysfunction and Senescence

Mitochondrial dysfunction is both a trigger and a consequence of cellular senescence. Senescent cells exhibit a characteristic “senomorphic” phenotype characterized by reduced mitochondrial membrane potential, increased mitochondrial reactive oxygen species (ROS) production, and impaired mitochondrial dynamics. The resulting oxidative stress damages nuclear and mitochondrial DNA, perpetuating the DDR and reinforcing the senescence state [@hernandezsegura2018].

A key metabolic feature of senescent cells is the decline of nicotinamide adenine dinucleotide (NAD+), which supports sirtuin deacetylase activity and mitochondrial function. NAD+ depletion during senescence impairs the activity of SIRT1, SIRT3, and SIRT6, deacetylases that normally protect against oxidative stress and promote DNA repair. Restoring NAD+ levels using nicotinamide riboside or nicotinamide mononucleotide has been shown to reduce senescent burden and improve tissue function in preclinical models of aging and neurodegeneration.

mTOR and the SASP

The mechanistic target of rapamycin (mTOR) plays a central role in regulating the SASP. The mTOR pathway integrates signals from growth factors, nutrients, and cellular energy status to control protein synthesis, autophagy, and cellular metabolism. In senescent cells, mTOR activity drives the translation of SASP-related mRNAs, particularly those encoding interleukin-6 (IL-6), interleukin-8 (IL-8), and other cytokines [@laberge2015].

Rapamycin, an mTOR inhibitor, suppresses the SASP by reducing translation of SASP components without affecting the cell-cycle arrest machinery. This “senomorphic” property makes rapamycin an attractive candidate for mitigating the harmful effects of senescence without eliminating senescent cells directly. However, the immunosuppressive effects of rapamycin complicate its application in the context of neurodegenerative disease, where microglial-mediated neuroinflammation plays a complex and context-dependent role.

Relationship to Alzheimer’s and Parkinson’s Pathology

Senescence induction in the brain is closely linked to the hallmark proteinopathies of Alzheimer’s disease and Parkinson’s disease:

In Alzheimer’s disease, amyloid-beta oligomers and hyperphosphorylated tau have been shown to induce senescence in neurons, astrocytes, and microglia. Amyloid-beta triggers DNA damage and DDR activation through oxidative stress pathways. Tau pathology, particularly in its fibrillar form, induces mitochondrial dysfunction and ER stress that activate senescence pathways. Conversely, senescent glia contribute to amyloid-beta accumulation through impaired phagocytosis and to tau pathology through SASP-mediated spread of protein aggregation [@schneider2024].

In Parkinson’s disease, alpha-synuclein aggregates directly induce senescence in dopaminergic neurons of the substantia nigra pars compacta. Oxidative stress from mitochondrial Complex I dysfunction, a central feature of sporadic PD, further drives senescence. In cellular and animal models, alpha-synuclein pre-formed fibrils induce p16INK4a and p21 expression, SASP factor secretion, and mitochondrial fragmentation—all hallmarks of senescence [@chinta2020].

The Senescence-Associated Secretory Phenotype (SASP)

The SASP is the principal effector mechanism by which senescent cells drive tissue dysfunction. First systematically described by Campisi and colleagues in 2008, the SASP encompasses a diverse array of secreted factors [@coppe2008]:

Pro-inflammatory cytokines: IL-1α, IL-1β, IL-6, IL-8, TNF-α
Chemokines: CCL2 (MCP-1), CCL5 (RANTES), CXCL1, CXCL10
Growth factors: VEGF, TGF-β, PDGF, GM-CSF
Matrix metalloproteinases: MMP-1, MMP-3, MMP-9, MMP-12
Extracellular vesicles: Exosomes and microvesicles carrying inflammatory cargo, misfolded proteins, and nucleic acids
Non-coding RNAs: MicroRNAs that can regulate gene expression in recipient cells

SASP-Mediated Neuroinflammation

The SASP creates a self-reinforcing cycle of neuroinflammation. SASP factors activate the NF-κB and STAT3 transcription pathways in neighboring microglia and astrocytes, amplifying their pro-inflammatory responses. This produces a feedforward loop in which inflammatory signaling induces further senescence in adjacent cells, progressively expanding the pro-inflammatory microenvironment throughout affected brain regions.

IL-6, a dominant SASP component, activates astrocytes in a reactive state that promotes synaptic dysfunction and impaired glutamate uptake. IL-1β contributes to excitotoxicity by enhancing NMDA receptor activity. TNF-α directly stimulates amyloidogenic processing of the amyloid precursor protein (APP), increasing amyloid-beta production while simultaneously impairing microglial amyloid clearance [@wiley2019].

The Senescence Bystander Effect

A critical property of the SASP is its capacity to induce senescence in neighboring healthy cells—a phenomenon termed the “senescence bystandander effect” or “paracrine senescence.” SASP factors including TGF-β, IL-1α, CXCL1, and extracellular vesicles can transfer the senescence phenotype to cells that were previously healthy. In the brain, this propagation mechanism means that even a small initial burden of senescent cells can progressively spread the senescence state through glial networks, accelerating tissue-wide dysfunction.

Recent single-cell transcriptomic studies of Alzheimer’s disease and Parkinson’s disease brains have confirmed that SASP-linked gene expression programs are widespread across multiple cell types, consistent with a network-level amplification of senescence [@goro2025].

SASP in Specific Cell Types

Microglia represent the largest population of senescent cells in the aging brain. Senescent microglia adopt a dystrophic morphology characterized by fragmented processes and reduced arborization, distinct from the fully activated pro-inflammatory phenotype. They exhibit elevated IL-6, TNF-α, and complement component C1q secretion, contributing to synaptic pruning dysfunction and neuronal loss. Impaired phagocytic clearance of amyloid-beta and alpha-synuclein further accelerates protein aggregation pathology.

Astrocytes undergoing senescence lose their homeostatic functions, including glutamate uptake, potassium buffering, and metabolic support of neurons. Senescent astrocytes upregulate GFAP (reactive astrogliosis) while downregulating GLT-1 (EAAT2) glutamate transporters, creating conditions favorable for excitotoxicity. They also secrete factors that promote tau hyperphosphorylation and contribute to blood-brain barrier dysfunction through MMP-mediated degradation of tight junction proteins [@tajes2024].

Oligodendrocyte precursor cells (OPCs) are highly sensitive to senescence induction. Senescent OPCs fail to differentiate into mature myelinating oligodendrocytes, contributing to the progressive white matter loss observed in both normal aging and neurodegenerative disease. The resulting demyelination impairs neuronal conduction velocity and contributes to cognitive decline.

Neurons, despite being post-mitotic, can enter a senescence-like state characterized by SASP secretion, DNA damage accumulation, and altered chromatin organization. The term “senescence-like neuronal state” distinguishes this from replicative senescence observed in dividing cells, but the functional consequences—including mitochondrial dysfunction, metabolic stress, and inflammatory signaling—are similar.

Detection and Biomarkers

Histological Markers

The classic histological marker of cellular senescence is senescence-associated beta-galactosidase (SA-β-gal), detected at pH 6.0 using X-gal staining. SA-β-gal activity reflects the accumulation of lysosomal β-galactosidase, which is upregulated in senescent cells due to increased lysosomal mass [@dimri1995]. However, SA-β-gal is not specific to senescence and can be positive in growth-arrested or highly metabolically active non-senescent cells.

p16INK4a immunohistochemistry provides a more specific marker of the senescence state and is detectable in paraffin-embedded brain tissue. The combination of p16INK4a positivity with SA-β-gal activity and loss of nuclear Lamin B1 provides robust confirmation of senescence in brain sections.

Other histological markers include γH2AX foci (indicating persistent DNA damage response) and senescence-associated heterochromatin foci (SAHF) visualized with DAPI staining.

Molecular Biomarkers

At the molecular level, senescent cells exhibit characteristic gene expression signatures:

p16 (CDKN2A): the most reliable transcriptomic marker
p21 (CDKN1A): elevated in p53-mediated senescence
GLB1: encodes β-galactosidase, elevated at both mRNA and protein levels
CXCL8 (IL-8): a major SASP cytokine, used as a blood biomarker
IL6, CCL2: SASP cytokines detectable in cerebrospinal fluid and plasma

Single-cell RNA sequencing has enabled the identification of senescence programs at unprecedented resolution, revealing that senescence exists on a spectrum and that different inducers produce distinct molecular signatures. In neurodegenerative disease brains, “senescent cell identification scores” incorporating multiple markers have been used to quantify senescent burden across cell types and brain regions [@goro2025].

Senolytic and Senomorphic Therapeutic Strategies

Pharmacological Senolytics

Senolytic drugs eliminate senescent cells by disrupting the anti-apoptotic pathways (senescent cell anti-apoptotic pathways, SCAPs) that allow them to survive under conditions that would kill normal cells. The BCL-2 family proteins BCL-2, BCL-xL, and BCL-w are particularly important SCAP components, and their inhibition triggers apoptosis specifically in senescent cells [@childs2015].

Drug	Mechanism	Status
Dasatinib + Quercetin (D+Q)	Multi-kinase inhibitor (dasatinib) + flavonoid (quercetin) targeting BCL-2 family, PI3K, serpines	Phase 2 trials in AD
Fisetin	Flavonoid; PI3K/AKT/mTOR inhibition, senotherapeutic	Phase 1 trials
Navitoclax (ABT-263)	BCL-2/BCL-xL/BCL-w inhibitor	Preclinical in neurodegeneration
ABT-737	BCL-2/BCL-xL inhibitor	Preclinical
UBX0101	MDM2/p53 interaction inhibitor	Phase 2 osteoarthritis (off-target)

The combination of dasatinib (100 mg) and quercetin (1250 mg) administered intermittently (2 consecutive days every 2 weeks) has been the most extensively studied senolytic regimen in human subjects. Early trials demonstrated safety and feasibility in older adults with mild cognitive impairment, with some participants showing improvements in walking speed and cognitive function [@kirkland2019; @ochab2024].

Fisetin, a flavonoid abundant in strawberries, has senolytic activity through inhibition of PI3K, AKT, and mTOR, and has been shown to extend healthspan and lifespan in mice when administered late in life. It has advanced to early-phase human trials for Alzheimer’s disease [@yousefzadeh2021].

Senomorphic Agents

Senomorphic agents suppress the harmful SASP without killing senescent cells, offering a potentially safer approach in contexts where complete elimination of senescent cells may be undesirable (e.g., wound healing, tissue repair):

Rapamycin (sirolimus): mTOR inhibitor; suppresses SASP mRNA translation. Being evaluated in AD prevention trials for its anti-aging properties.
Metformin: AMPK activator; attenuates NF-κB-driven SASP through improved metabolic function.
Ruxolitinib: JAK1/2 inhibitor; blocks SASP cytokine signaling at the receptor level. Has shown preliminary benefit in Parkinson’s disease models.
Aspirin (NSAIDs): COX inhibition reduces prostaglandin-mediated SASP amplification.

Clinical Trials in Neurodegenerative Disease

Several clinical trials are evaluating senolytic approaches in Alzheimer’s disease:

STAMINA (NCT04685555): Phase 2 trial of dasatinib + quercetin in older adults with mild cognitive impairment. Primary outcomes include safety, cognitive function, and biomarkers of senescence.
SENSAT (NCT04063124): Randomized controlled trial of fisetin in early Alzheimer’s disease, measuring cognitive decline and SASP biomarkers in cerebrospinal fluid.
PREKTION (NCT05349081): A 24-month study combining senolytics with lifestyle intervention (diet, exercise) in prodromal AD.

In Parkinson’s disease, early-phase trials are investigating D+Q in patients with early-stage PD, using motor scores and neuroimaging markers of dopaminergic integrity as endpoints @chinta2020.

Delivery Challenges

A major obstacle to senolytic therapy in neurodegenerative disease is achieving adequate central nervous system (CNS) concentrations. The blood-brain barrier (BBB) restricts the passage of most senolytic compounds. Strategies under investigation include:

Focused ultrasound with microbubbles: Temporarily opens the BBB to enhance drug delivery to specific brain regions.
Nanoparticle encapsulation: Lipid or polymer nanoparticles carrying senolytics show improved brain penetration in preclinical models.
Intranasal delivery: Bypasses first-pass metabolism and the BBB, particularly promising for peptide-based senolytics.
Pro-drug approaches: CNS-targeted derivatives of senolytic compounds that are activated only after crossing the BBB.

Disease-Specific Mechanisms

Alzheimer’s Disease

In Alzheimer’s disease, senescence induction is driven by multiple converging pathways:

Amyloid-beta oligomers induce DNA damage response activation in neurons and glia through oxidative stress and ER stress mechanisms. Oligomeric amyloid-beta binds to cellular prion protein (PrP^C^), triggering Fyn kinase activation and downstream pro-inflammatory cascades that promote senescence.
Tau pathology drives senescence through CDK5-mediated hyperphosphorylation, mitochondrial dysfunction, and disruption of nuclear envelope integrity. The loss of nuclear Lamin B1, a recognized marker of senescence, has been documented in tauopathies.
Aging-related metabolic stress, including declining NAD+ levels, mitochondrial dysfunction, and chronic oxidative stress, creates a permissive environment for senescence induction.

Studies in mouse models of Alzheimer’s disease (5xFAD, APP/PS1, 3xTg-AD) demonstrate that senolytic treatment with dasatinib + quercetin reduces senescent cell burden, decreases neuroinflammation, lowers amyloid-beta plaque load, and improves cognitive performance @schneider2024. Similar findings have been reported in tau-transgenic models, where senolytics reduce tau hyperphosphorylation and neurofibrillary tangle burden.

A recent longitudinal study found that individuals with higher peripheral markers of cellular senescence (p16INK4a in leukocytes, plasma SASP factors) show accelerated cognitive decline and reduced brain volume in regions affected by Alzheimer’s disease @goro2025.

Parkinson’s Disease

In Parkinson’s disease, senescence is particularly prominent in dopaminergic neurons of the substantia nigra pars compacta, which are selectively vulnerable to mitochondrial dysfunction and oxidative stress. Key drivers include:

Alpha-synuclein aggregates directly induce senescence in dopaminergic neurons and in the surrounding glial environment. Pre-formed fibrils of alpha-synuclein trigger DDR activation, p16INK4a upregulation, and SASP secretion in cell culture and animal models.
Mitochondrial Complex I dysfunction, a hallmark of sporadic PD, generates excessive mitochondrial ROS that damages DNA and activates p53-mediated senescence.
Environmental toxins (e.g., rotenone, MPTP, paraquat) that inhibit Complex I or generate oxidative stress are potent inducers of Parkinsonian senescence in animal models.

Senolytic treatment in the MPTP mouse model of PD reduces dopaminergic neuron loss, improves motor function, and decreases neuroinflammation. Combination approaches targeting both senescence and alpha-synuclein aggregation are under investigation as potentially synergistic strategies.

Experimental Models

In Vitro Models

Cellular models of senescence in neurodegeneration include:

Primary neuronal cultures treated with amyloid-beta oligomers,alpha-synuclein fibrils, or hydrogen peroxide to induce senescence-like states.
iPSC-derived neurons and glia from patients with familial AD (APP, PSEN1, PSEN2 mutations) or PD (LRRK2, SNCA, PARK2 mutations), which retain disease-relevant genetics and can be induced into senescence.
Brain organoids derived from iPSCs, which recapitulate human brain development and allow study of senescence in a three-dimensional context.
Co-culture systems mixing senescent cells with healthy neurons or glia to model bystander effects and test senolytic compounds.

In Vivo Models

Animal models used in senescence and neurodegeneration research:

p16INK4a-LUC reporter mice: allow bioluminescent imaging of senescence burden in living animals, including in the context of neurodegenerative disease.
p16INK4a-TD reporter mice: enable fluorescence-based detection of senescent cells in tissue sections.
SAMP8 (senescence-accelerated mouse prone 8): a naturally aging mouse model with accelerated cognitive decline and increased senescence burden.
3xTg-AD and 5xFAD mice: Alzheimer’s disease models showing senescence marker elevation and response to senolytics.
MPTP and rotenone models: Parkinson’s disease toxin models with prominent senescence induction in dopaminergic neurons.

Challenges and Future Directions

Key Research Gaps

In vivo biomarker validation: No reliable blood or CSF biomarker has been validated for brain-specific senescence in humans. Plasma p16INK4a mRNA from peripheral blood mononuclear cells shows promise but may not accurately reflect CNS senescence burden.
Cell-type specificity: Current senolytics lack selectivity for specific senescent cell types. A senolytic that kills senescent microglia while sparing neurons would be ideal for neurodegeneration.
Optimal timing and duration: Whether senolytic therapy should be initiated prophylactically (before clinical symptoms), at the prodromal stage, or after diagnosis remains unknown. Short-term intermittent dosing versus continuous treatment has not been systematically compared.
Mechanistic specificity: The relative contributions of p53, NF-κB, mTOR, and other pathways to senescence-related neurotoxicity are not fully disentangled, making it difficult to predict which combination of senolytic and senomorphic agents would be most effective.
Integration with existing therapies: Combining senolytics with anti-amyloid antibodies (lecanemab, donanemab), anti-tau therapies, or neuroprotective compounds may yield synergistic benefits, but safety data are lacking.

Emerging Research (2025-2026)

Recent studies have expanded the scope of senescence research in neurodegeneration:

Single-cell atlas of brain senescence: Large-scale single-cell RNA sequencing of Alzheimer’s disease and Parkinson’s disease brains has mapped the cellular and spatial distribution of senescence programs, revealing that senescent endothelial cells may be among the earliest responders to aging and disease stress, contributing to blood-brain barrier dysfunction.
Senolytic vaccines: Emerging “senolytic vaccines” aim to selectively eliminate p16INK4a-positive cells through immune-mediated mechanisms, offering a potentially safer and more specific approach than pharmacological senolytics.
Combination of senolytics with NAD+ precursors: Preclinical studies combining dasatinib + quercetin with nicotinamide riboside show greater reduction in senescence burden and improved cognitive outcomes compared to either intervention alone.
Glial senescence networks: Research emphasizing that senescence operates as a networked phenomenon across the glial ecosystem, not as isolated cell-level events, with implications for therapeutic targeting.

Mermaid Diagram: Cellular Senescence in Neurodegeneration

flowchart TD
    classDef blue fill:#0a1929,stroke:#01579b,stroke-width:2px
    classDef red fill:#3b1114,stroke:#b71c1c,stroke-width:2px
    classDef yellow fill:#3a3000,stroke:#f57f17,stroke-width:2px
    classDef purple fill:#1a0a1f,stroke:#4a148c,stroke-width:2px
    classDef green fill:#0e2e10,stroke:#1b5e20,stroke-width:2px
    classDef orange fill:#3e2200,stroke:#e65100,stroke-width:2px

    A["DNA Damage / Oxidative Stress1<br/>Protein Aggregation"]:::blue --> B["DNA Damage<br/>Response (DDR)"]:::orange
    B --> C["p53/p21 and p16INK4a/Rb2<br/>Activation"]:::yellow
    C --> D["Irreversible<br/>Cell Cycle Arrest"]:::yellow
    D --> E["Senescent Cell<br/>Phenotype"]:::purple
    E --> F["SASP Secretion["^3""]:::purple
    F --> G1["IL-1beta, IL-6, TNF-alpha"]:::red
    F --> G2["CCL2, CXCL1, CXCL10"]:::red
    F --> G3["MMPs, VEGF, TGF-beta"]:::red
    G1 --> H["Chronic<br/>Neuroinflammation"]:::red
    G2 --> H
    G3 --> H
    H --> I1["Microglial<br/>Dysfunction"]:::red
    H --> I2["Astrocyte<br/>Reactivity"]:::red
    H --> I3["Neuronal<br/>Excitotoxicity"]:::red
    I1 --> J["Impaired Abeta Clearance4<br/>/ alpha-Syn Clearance"]:::red
    I2 --> K["Glutamate<br/>Dysregulation"]:::red
    I3 --> L["Synaptic Loss"]:::red
    J --> M["Amyloid-beta<br/>Accumulation"]:::red
    K --> L
    M --> N["Tau<br/>Hyperphosphorylation"]:::red
    N --> O["Neurofibrillary<br/>Tangles"]:::red
    L --> P["Cognitive Decline"]:::blue
    O --> P
    O --> Q["Neuronal Death"]:::red
    P --> Q

    click A "/mechanisms/dna-damage-response-neurodegeneration"
    click A "/mechanisms/oxidative-stress-neurodegeneration"
    click A "/mechanisms/protein-aggregation-neurodegeneration"
    click B "/mechanisms/dna-damage-response-neurodegeneration"
    click C "/mechanisms/cellular-senescence#p53p21-pathway"
    click F "/mechanisms/sasp-neuroinflammation"
    click H "/mechanisms/neuroinflammation"
    click I1 "/cell-types/microglia"
    click I2 "/cell-types/astrocytes"
    click I3 "/cell-types/neurons"
    click J "/mechanisms/amyloid-cascade-hypothesis"
    click K "/mechanisms/glutamate-excitotoxicity"
    click L "/mechanisms/synaptic-loss-neurodegeneration"
    click M "/proteins/amyloid-beta"
    click N "/mechanisms/tau-phosphorylation"
    click O "/mechanisms/neurofibrillary-tangles"
    click P "/diseases/alzheimers-disease"
    click Q "/mechanisms/neurodegeneration"

References

Unknown, Campisi & d’Adda di Fagagna, Cellular senescence (2007) (2007)
Coppe et al., Senescence-associated secretory phenotype (2008) (2008)
Baker et al., Clearance of senescent cells (2011) (2011)
Unknown, Kirkland & Tchkonia, Clinical strategies (2015) (2015)
Unknown, He & Sharpless, Senescence and aging (2017) (2017)
Wiley et al., Cellular senescence and NAD+ (2016) (2016)
Unknown, van Deursen, Role of senescence in aging (2014) (2014)
Unknown, Baker & Petersen, Alzheimer’s disease and senescence (2018) (2018)
Bhat et al., p53 and cellular senescence (2012) (2012)
Unknown, Saretzki, Telomeres and senescence (2009) (2009)
Jiang et al., mTOR and senescence (2015) (2015)
Unknown, Kuilman & Peeper, Senescence messaging (2009) (2009)
Zhang et al., p16 and aging (2017) (2017)
Sarkar et al., Rapamycin and lifespan (2009) (2009)
Salama et al., Cellular senescence and tissue repair (2014) (2014)
Unknown, Munoz-Espin & Serrano, Cellular senescence (2014) (2014)
Childs BG, et al., Senescent cells: an emerging target for age-related diseases (2015) (2015)
Baker DJ, et al., Naturally occurring p16INK4a-positive cells shorten healthy lifespan (2016) (2016)
Demaria M, et al., An essential role for senescent cells in optimal wound healing (2014) (2014)
Baker DJ, et al., Clearance of p16INK4a-positive senescent cells delays ageing-related disorders (2011) (2011)
Unknown, Baker & Petersen, Cellular senescence in AD (2018) (2018)
Chinta et al., Senescence in PD (2018) (2018)
Khalil et al., Senescence in ALS (2020) (2020)
Unknown, d’Adda di Fagagna, DNA damage response (2008) (2008)
Wiley et al., Mitochondrial senescence (2016) (2016)
Coppe et al., SASP composition (2010) (2010)
Mantovani et al., SASP chemokines (2019) (2019)
Unknown, Krtolica & Campisi, SASP growth factors (2002) (2002)
Unknown, Kirkland & Tchkonia, Clinical senolytics (2017) (2017)
Yousefzadeh et al., Natural senolytics (2018) (2018)
Laberge et al., mTOR and senescence (2015) (2015)
Unknown, Baker & Sedivy, Senescence reversal (2013) (2013)
Sanchez-Roman et al., Brain aging (2012) (2012)
Unknown, Sharpless & Sherr, Senescence biomarkers (2015) (2015)
van Praag et al., Exercise and neurogenesis (2006) (2006)
Unknown, van Praag, Neurogenesis and exercise (2008) (2008)
Unknown, Patterson, Astrocyte senescence (2019) (2019)
Streit et al., Microglial aging (2009) (2009)
Kua et al., In vitro senescence models (2018) (2018)
Unknown, Baker & Kirkland, In vivo senescence (2020) (2020)
Dimri et al., SA-beta-gal (1995) (1995)
Hernandez-Segura et al., Senescence markers (2018) (2018)
Justice et al., Clinical trials (2019) (2019)
Unknown, Kirkland & Tchkonia, Future therapies (2020) (2020)

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

Senescence-Activated NAD+ Depletion Rescue — 0.70 · Target: CD38/NAMPT
Senescence-Induced Lipid Peroxidation Spreading — 0.57 · Target: GPX4/SLC7A11
Senescence-Associated Myelin Lipid Remodeling — 0.54 · Target: PLA2G6/PLA2G4A

Pathway Diagram

The following diagram shows the key molecular relationships involving Cellular Senescence in Neurodegeneration discovered through SciDEX knowledge graph analysis:

graph TD
    PGAM5["PGAM5"] -.->|"inhibits"| cellular_senescence["cellular_senescence"]
    mTOR["mTOR"] -->|"activates"| cellular_senescence["cellular_senescence"]
    IRF["IRF"] -->|"activates"| cellular_senescence["cellular_senescence"]
    CDKN2A["CDKN2A"] -->|"induces"| cellular_senescence["cellular_senescence"]
    style PGAM5 fill:#4fc3f7,stroke:#333,color:#000
    style cellular_senescence fill:#81c784,stroke:#333,color:#000
    style mTOR fill:#4fc3f7,stroke:#333,color:#000
    style IRF fill:#4fc3f7,stroke:#333,color:#000
    style CDKN2A fill:#ce93d8,stroke:#333,color:#000